The low overall incidence rates of myocardial infarction (0.7%) and stroke (0.3%) reported in this study are consistent with those of a previous randomized controlled trial in which PCSK9 inhibition with evolocumab reduced the overall rate of myocardial infarction and stroke in patients with atherosclerotic CVD.16 This evidence concerns the gene PCSK9 and Stroke.